Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT Followed by Adebrelimab and Lenvatinib for HCC with Abdominal Lymph Node Metastases
NCT06261125Phase 2Recruiting
- Sponsor
- Mianxi Biopharma
- Start
- Mar 2024
- Primary completion
- Jun 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab in hepatocellular carcinoma (HCC), sponsored by Mianxi Biopharma. Started Mar 2024; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06261125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06261125.